Compare RRBI & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRBI | LAB |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.2M | 488.4M |
| IPO Year | 2019 | 2011 |
| Metric | RRBI | LAB |
|---|---|---|
| Price | $91.40 | $1.28 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $67.00 | $1.35 |
| AVG Volume (30 Days) | 42.4K | ★ 1.2M |
| Earning Date | 01-30-2026 | 02-25-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | ★ 26.56 | N/A |
| EPS | ★ 6.01 | N/A |
| Revenue | $119,363,000.00 | ★ $169,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.83 | N/A |
| P/E Ratio | $15.15 | ★ N/A |
| Revenue Growth | 12.57 | ★ 79.77 |
| 52 Week Low | $46.33 | $0.92 |
| 52 Week High | $93.90 | $1.72 |
| Indicator | RRBI | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 83.99 | 38.14 |
| Support Level | $76.15 | $1.24 |
| Resistance Level | $91.85 | $1.46 |
| Average True Range (ATR) | 2.57 | 0.09 |
| MACD | 1.58 | -0.03 |
| Stochastic Oscillator | 100.00 | 9.30 |
Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.